Research Article

Relationship between Traditional Chinese Medicine Syndrome Elements and Prognosis of Patients with IgA Nephropathy

Jianghua Ke,1,2 Shuwei Duan,1 Linchang Liu,1 Zhiwei Yin,1 Shuang Li,1 Yujing Ke,1,2 Jin Yao,1,2 Ying Zheng,1 Weiguang Zhang,1 Yilun Qu,1,2 Ping Li,1,2 Zheyi Dong,1 and Xiangmei Chen1,2

1National Clinical Research Center for Kidney Diseases, State Key Laboratory of Kidney Diseases, Beijing Key Laboratory of Kidney Disease Research, First Medical Center of Chinese PLA General Hospital, Nephrology Institute of the Chinese People’s Liberation Army, Beijing 100853, China
2School of Clinical Medicine, Guangdong Pharmaceutical University, Guangzhou 510006, China

Correspondence should be addressed to Xiangmei Chen; xmchen301@126.com

Jianghua Ke and Shuwei Duan contributed equally to this work.

Received 15 April 2022; Accepted 27 June 2022; Published 30 July 2022

Academic Editor: Yanggang Yuan

Copyright © 2022 Jianghua Ke et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. It is not clear which Traditional Chinese Medicine-(TCM-) related elements affect primary IgA nephropathy (IgAN) progression. Here, we explored the risk factors, based on TCM syndrome elements, related to the prognosis of primary IgAN patients. Methods. We analyzed patients with newly diagnosed, biopsy-proven IgAN at a single institution from December 2013 to September 2021. Basic clinical and pathological characteristics were assessed at the time of renal biopsy. The study endpoint was end-stage renal disease (ESRD: eGFR < 15 ml/min per 1.73 m², dialysis, or kidney transplantation) and/or eGFR decreased by >30% from baseline. Kaplan–Meier survival analysis was used to explore the role of TCM syndrome elements in IgAN progression. Multivariate Cox regression analysis with adjustment for traditional risk factors was performed to explore TCM syndrome elements that may influence patient prognosis. The factors correlated with TCM syndrome elements in IgAN patients were further evaluated by logistic regression analysis. Results. During a median follow-up of 22.0 months, 53 (12.5%) of the 423 included IgAN patients reached the study endpoint. The main IgAN disease location elements were the kidney, liver, and spleen. The main IgAN disease nature elements were Yin-deficiency and Qi-deficiency, dampness, Yang-deficiency, phlegm, and Blood-deficiency. Kaplan–Meier analysis identified three disease locations (liver, spleen, and kidney) and four disease natures (Qi-deficiency, Yang-deficiency, phlegm, and dampness) as elements associated with poor renal survival in IgAN patients. In multivariate Cox regression analysis, baseline Yang-deficiency was an independent risk predictor of poor prognosis in primary IgAN patients (hazard ratio 2.338; 95% confidence interval [CI]: 1.208–4.525; \( P = 0.012 \)) after adjustment for traditional risk factors. Furthermore, logistic regression analysis identified being female (odds ratio [OR] 2.518; 95% CI: 1.538–4.122; \( P < 0.001 \)), older age (OR 1.043; 95% CI: 1.022–1.065; \( P < 0.001 \)), low hemoglobin levels (OR 0.984; 95% CI: 0.971–0.996; \( P = 0.013 \)), and cellular/fibrocellular crescents (OR 1.706; 95% CI: 1.068–2.728; \( P = 0.026 \)) as factors affecting Yang-deficiency in IgAN patients. Conclusions. Yang-deficiency independently predicts the risk of poor prognosis in primary IgAN patients. Being female, older age, low hemoglobin levels, and cellular/fibrocellular crescents were independently associated with Yang-deficiency in IgAN patients.

1. Introduction

IgA nephropathy (IgAN) is the most common primary glomerular disease in the world [1, 2], with an incidence of more than 2.5 cases per 100,000 people [3]. It is also the main cause of chronic kidney disease and end-stage renal disease (ESRD) [1, 4], placing a heavy economic and social burden on countries and individuals. The clinical and pathological manifestations of IgAN patients are diverse, and individual prognosis varies greatly. Early detection of risk factors for disease progression is of great significance for delaying the development of disease and improving the prognosis of patients.
At present, the Kidney Disease International Global Outcomes (KDIGO) guidelines [4] recommend that the international prediction tool [5] be used to assess the progression risk of IgAN patients. The internal verification accuracy of the prediction model reaches 80%, and the external verification [6, 7] also shows good prediction ability. However, in about 25% of patients, it will develop into renal insufficiency within 10 years even in those with clinically early IgAN. Consequently, there is still a lack of more risk factors for IgAN.

Traditional Chinese Medicine (TCM) uses syndrome differentiation and treatment as the core and has unique advantages in delaying the progress of IgAN [8–10]. Syndrome differentiation used the basic theory of TCM to elucidate the nature of the disease through its external expression. It is also the premise of treatment (legislation, prescription, and medication), which is highly empirical and subjective, and is not conducive to quantitative diagnosis.

TCM syndrome element differentiation is a new syndrome differentiation system put forward by professors Wenfeng Zhu and Yongyan Wang [11–13], which facilitates quantification of TCM syndrome differentiation [14–16]. TCM syndrome elements are the indecomposable diagnostic units that make up the syndrome, with independent connotation, including disease location syndrome elements, such as the heart, liver, or spleen, and disease nature syndrome elements, such as Qi deficiency, blood stasis, or phlegm.

In the past, numerous studies have investigated the prognosis of IgAN in the context of TCM, mostly focusing on exploring the prognostic differences between different syndrome types [17, 18]. However, it was unclear which TCM-related risk factors affected the progress of IgAN. In this study, we explored the impact of TCM syndrome elements on the prognosis of IgAN.

2. Materials and Methods

2.1. Participants. Overall, 722 patients with primary IgA nephropathy, newly diagnosed by renal biopsy in the first medical center of the Chinese People’s Liberation Army General Hospital from December 2013 to September 2021, were retrospectively screened. The inclusion criteria were as follows: (1) estimated glomerular filtration rate (eGFR) ≥ 15 ml/min per 1.73 m² at the time of renal biopsy; (2) age 18 years or older at the time of renal biopsy, regardless of sex; and (3) availability of records of the four diagnoses of TCM. The exclusion criteria were as follows: (1) fewer than eight glomeruli available at biopsy; (2) secondary IgA nephropathy, such as hepatitis B-associated nephritis, anaphylactoid purpura nephropathy, systemic lupus erythematosus nephritis, and so on; (3) systemic diseases, such as diabetes, connective tissue disease, and so on; (4) patients with follow-up of less than 90 days; (5) lack of results of TCM syndrome factor evaluation; and (6) incomplete medical records. According to the inclusion and exclusion criteria, 423 patients were included in the analysis (Figure 1). This study was in accordance with the Declaration of Helsinki and approved by the Research Ethics Committee of the first medical center of the Chinese People’s Liberation Army General Hospital (Approval no. S2021-165-01), and all subjects had signed an informed consent.

2.2. Clinical Data. Baseline clinical and laboratory data were collected at the time of renal biopsy. This information included sex, age, body mass index (BMI), mean arterial pressure (MAP) that was calculated as diastolic blood pressure (BP) + 1/3 (systolic BP – diastolic BP), total serum protein, serum albumin (ALB), blood urea nitrogen (BUN), serum creatinine, serum uric acid (SUA), eGFR, calculated by the Chronic Kidney Disease Epidemiology Collaboration equation adjusted for Asian populations [19], total cholesterol, triglycerides, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), 24 h urinary protein, hemoglobin (Hb), urine red blood cell count (URBC), and the use of renin-angiotensin system blocker (RASB) and immunosuppression. The use of RASB, including angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers, and immunosuppression were defined as any exposure to these treatments at or prior to kidney biopsy.

2.3. Evaluation of Renal Histopathological Damage. The pathological diagnosis was confirmed by two pathologists and was reevaluated according to the Oxford classification [20]. Both pathologists were blinded to the clinical data. When the two pathologists’ scores differed, a third pathologist rescored the images. A final score was decided after discussion among three pathologists. The Oxford classification: mesangial hypercellularity, a mesangial score ≤0.5 was recorded as M0, a mesangial score >0.5 was recorded as M1; endocapillary hypercellularity, E0: absent or E1: present; segmental glomerulosclerosis or adhesion, S0: absent or S1: present; tubular atrophy/interstitial fibrosis, T0 ≤ 25%, T1: 26%–50%, or T2 > 50%; and cellular/fibrocellular crescents, C0: absent, C1 < 25% or C2 ≥ 25% of glomeruli.

2.4. Primary Outcome Definitions. The primary outcome was a composite event including the first occurrence of either a 30% decline in eGFR from the value at biopsy or end-stage renal disease (ESRD: eGFR <15 ml/min per 1.73 m², dialysis, or kidney transplantation).

2.5. Traditional Chinese Medicine Materials. We collected the TCM four diagnosis within 7 days before and after renal biopsy, including symptoms, signs, tongue, and pulse. TCM syndrome elements included disease location syndrome elements, such as the heart, liver, or spleen, and disease nature syndrome elements, such as Qi deficiency, blood stasis, or phlegm. TCM syndrome element was diagnosed according to the " Syndrome element differentiation" compiled by Professor Wenfeng Zhu, which involved identifying the syndrome element and the score of the syndrome element corresponding to each symptom in the syndrome differentiation factor scale. Each symptom was divided into no, mild, moderate, and severe grade (4), the main complaint or severe symptom, the score multiplied by 1.5; or moderate symptom, the score multiplied by 1; or mild symptom, the score multiplied by 0.7. When the sum of the score of the TCM for diagnosis of the syndrome element reaches or exceeds 100 points, these syndrome elements can be diagnosed.
2.6. Statistical Analysis. Statistical analysis was performed using SPSS version 26.0 (IBM SPSS Corp., Armonk, NY, USA). Continuous variables were expressed as the mean ± standard deviation for normally distributed data, as the median of the interquartile range (IQR) (25%, 75%) for nonnormally distributed data, and the constituent ratio of qualitative data was expressed as frequency (percentage). Comparisons between groups were performed using Student’s t-test, Mann–Whitney U test, or chi-squared test. The cumulative renal survival rate was calculated using Kaplan–Meier survival curves, which were compared by log-rank test. Multivariate Cox proportional hazard regression models were used to analyze the factors affecting the prognosis of patients with IgAN. Multivariate logistic regression was used to analyze the correlation between TCM syndrome factors and clinicopathological indexes. A p-value < 0.05 was considered statistically significant (two-sided).

3. Results

3.1. Clinical and Pathological Characteristics of Patients with IgA Nephropathy. Of the 722 patients screened, 423 patients with biopsy-proven IgAN met the selection criteria and were included in this study (Figure 1). The clinical and pathological characteristics of the patients were summarized in Table 1. According to the KDIGO 2021 clinical practice guideline [4], patients were classified into five chronic kidney disease (CKD) stages by eGFR levels.

There were 155 (21.5%) patients with <90 days’ follow-up who were excluded. Baseline comparisons of the 423 patients including those followed up for <90 days were shown in Supplementary Table S1 and Table S2. There were no significant differences in TCM syndrome elements or clinical and pathological characteristics between the included and excluded groups.

After a median follow-up of 22.0 months (IQR 6.0, 56.0), 53 (12.5%) patients experienced the primary outcome, including 31 (7.3%) patients with a 30% decrease in eGFR and 22 (5.2%) patients who developed ESRD.

3.2. Distribution of Syndrome Elements of Patients with IgA Nephropathy. A total of 423 patients with IgAN were assessed for eight syndrome elements of disease location. Kidney was the most common location, followed by liver and spleen, while the lung, heart, stomach, Biao, and Jifu were less often involved (Table 2). Eleven syndrome elements of the disease nature of 423 patients were listed in Table 2. Yin-deficiency and Qi-deficiency had the highest frequency, followed by dampness, Yang-deficiency, phlegm, Blood-deficiency, with Blood-stasis, heat, water retention, Qi-depression, and Yang-hyperactivity being less frequent.

3.3. Kaplan–Meier Curves of Cumulative Renal Survival by Traditional Chinese Medicine Syndrome Elements. Kaplan–Meier analysis indicated that there were seven syndrome elements that were related to poor renal survival in IgAN patients, including three disease location elements and four disease nature elements. The disease location elements were liver, spleen, and kidney, while the disease nature elements were Qi-deficiency, Yang-deficiency, phlegm, and dampness. The difference was statistically significant at P < 0.05 (Figure 2).

3.4. Risk Factors for Kidney Prognosis in IgAN Patients. Multivariate Cox proportional hazard regression analysis was performed to explore the risk factors that may influence the prognosis of patients with IgAN. Traditional risk factors (age, MAP, eGFR, proteinuria, immunosuppressant use,


3.5. Analysis of Factors Influencing Yang-Deficiency in Patients with IgA Nephropathy. Since Yang-deficiency was an independent risk factor affecting the prognosis of IgAN patients, we further performed univariate and multivariate logistic regression analyses to explore the factors correlated with Yang-deficiency in patients with IgAN. Univariate logistic regression analysis showed that being female, older age, endocapillary hypercellularity, cellular/fibrocellular crescents, higher levels of HDL-C and URBC, and a lower level of ALB, SUA, and Hb were statistically significantly associated with Yang-deficiency (P < 0.05, Table 4). It suggested that patients with Yang-deficiency had a more severe pathological lesion than those without Yang-deficiency. After the variables were screened, the major factors identified included being female, older age, lower Hb levels, and cellular/fibrocellular crescents (P < 0.05, Table 4).

And we analyzed the relationship between the Yang-deficiency in patients with CKD stages or 24h urinary protein at the time of renal biopsy, two important characteristics of patients with IgAN. The 423 patients were divided into Yang-deficiency group (147, 34.8%) and non-Yang-deficiency group (276, 65.2%). At the time of renal biopsy, two important characteristicsof patients with IgAN. The 423 patients weredivided into Yang-deficiency group (147, 34.8%) and non-Yang-deficiency group (276, 65.2%). At the time of renal biopsy, there were no statistical differences between the two groups in eGFR, CKD stages and 24h urinary protein (Table S3).

4. Discussion

In this study, using TCM syndrome element analysis of IgAN, the main disease location elements of IgAN were kidney, liver, and spleen, while the main disease nature elements of IgAN were Yin-deficiency and Qi-deficiency, dampness, Yang-deficiency, phlegm, and Blood-deficiency. Yang-deficiency was identified as an independent risk factor for poor prognosis of IgAN. The factors related to Yang deficiency were being female, older, having a low Hb level, and cellular/fibrocellular crescents.

With a view of additional risk factors, we adjusted the prognostic factors of IgAN, as recommended by international guidelines [4]; we found that Yang-deficiency was still an independent risk factor for poor prognosis in IgAN patients. Previous studies had also reported that a Yang-deficiency constitution is related to the prognosis in IgAN patients [17]. The urinary protein level was the highest, the renal function was the worst, and the pathological damage was the most severe in IgAN patients with spleen–kidney Yang-deficiency syndrome [18, 21]. Huangqi Guizhi Wuwu decoction, a classic prescription, with the functions of supplementing Qi, warming Yang, removing blood stasis, and dredging collaterals, had also been proved to alleviate proteinuria and protect renal function in IgAN patients with spleen–kidney Yang-deficiency syndrome [22]. Traditional Chinese medicine believed that Yang Qi can stimulate and promote the physiological functions of human tissues and organs and promote the production and operation of blood, as well as the production, distribution, and excretion of body fluids.
Table 2: Distribution of syndrome elements in IgAN patients (n (%)).

| Syndrome elements of disease location | Frequency | Syndrome elements of disease nature | Frequency |
|--------------------------------------|-----------|-------------------------------------|-----------|
| Kidney                               | 371 (87.7)| Yin-deficiency                      | 334 (79.0)|
| Liver                                | 212 (50.1)| Qi-deficiency                       | 204 (48.2)|
| Spleen                               | 154 (36.4)| Dampness                            | 154 (36.4)|
| Lung                                 | 46 (10.9) | Yang-deficiency                     | 147 (34.8)|
| Heart                                | 30 (7.1)  | Phlegm                              | 144 (34.0)|
| Stomach                              | 10 (2.4)  | Blood-deficiency                    | 136 (32.2)|
| Biao                                 | 8 (1.9)   | Blood-stasis                        | 65 (15.4) |
| Jifu                                 | 7 (1.7)   | Heat                                | 53 (12.5) |
|                                      |           | Water retention                      | 37 (8.7)  |
|                                      |           | Qi-depression                        | 36 (8.5)  |
|                                      |           | Yang-hyperactivity                   | 23 (5.4)  |

Figure 2: Continued.
fluid. Yang-deficiency is mainly located in the spleen, kidney, and heart, and kidney Yang-deficiency is generally considered to be the most important. Deficiency of kidney Yang weakens the promotion of the production and the movement of blood; then it leads to anemia. Similarly, deficiency of kidney Yang was unable to promote the production, distribution, and excretion of body fluid; then the urination volume decreases and edema is observed clinically.

This study found that the proportion of patients with Yang-deficiency syndrome was higher among female than among male patients with IgAN. Previous studies have also shown that women are more common in the population with Yang-deficiency [23, 24], and that being female is positively correlated with Yang-deficiency [25]. In TCM, men and women are considered to have different endowments of Yin and Yang. Men have more Yang and less Yin, while women have more Yin and less Yang. Women prefer more stillness and less movement, which can easily lead to Yang-deficiency. At the same time, Yang-deficiency in men is considered to be a manifestation of more serious disease, which is consistent with previous studies that found that the prognosis of male patients with IgAN was worse [26–28].

In this study, age was a positive predictor of Yang-deficiency in patients with IgAN, which is consistent with the TCM theory that human Yang decreases with increasing age. Chen et al. used a multicenter, epidemiological, on-the-spot investigation to study the TCM syndromes of 1,016 patients with IgAN [18]. They found that, with increased age, the proportion of patients with spleen–lung Qi-deficiency syndrome decreased, while the proportion of spleen–kidney Yang-deficiency syndrome increased [18]. Tang et al. proposed that, with the increase in age, the proportion of individuals with liver and kidney Yin (Qi)-deficiency syndrome decreased, while the proportion of those with
spleen and kidney (Qi) Yang-deficiency syndrome increased [29]. In addition, IgAN usually occurs in young adults. With increasing age, the course of the disease was prolonged. Over a long period of time, true Yang can be damaged, which may also be one of the factors leading to the positive correlation between age and IgAN Yang-deficiency. In this study, the Hb level of patients with Yang-deficiency was lower. Previous studies also found that the level of hemoglobin in Yang-deficiency syndrome group was significantly lower than that in Qi-deficiency syndrome group and Qi-Yin deficiency syndrome group [30]. Hb is the basis for the diagnosis of anemia. Renal anemia is not only a

| Variables                  | Multivariate Cox proportional hazard regression analysis on the prognosis of IgAN patients. |
|----------------------------|------------------------------------------------------------------------------------------|
|                            | HR                        | 95% CI          | P       |
| Yang-deficiency            | 2.338                     | 1.208–4.525     | 0.012   |
| Age                       | 1.006                     | 0.967–1.046     | 0.781   |
| MAP                       | 1.009                     | 0.984–1.035     | 0.465   |
| M                         | 1.200                     | 0.625–2.302     | 0.584   |
| E                         | 0.670                     | 0.279–1.607     | 0.369   |
| S                         | 0.975                     | 0.430–2.213     | 0.952   |
| T                         | —                         | —               | 0.909   |
| T0                        | —                         | —               | —       |
| T1                        | 1.546                     | 0.556–4.304     | 0.404   |
| T2                        | 2.716                     | 1.009–7.316     | 0.048   |
| Immunosuppressant use      | 0.643                     | 0.325–1.271     | 0.204   |
| RASB use                  | 1.137                     | 0.397–3.257     | 0.812   |
| eGFR                      | 0.983                     | 0.969–0.997     | 0.019   |
| 24h urinary protein        | 1.199                     | 1.022–1.407     | 0.026   |

MAP: mean arterial pressure; M: mesangial hypercellularity; E: endocapillary hypercellularity; S: segmental glomerulosclerosis or adhesion; T: tubular atrophy/interstitial fibrosis; RASB: renin-angiotensin system blocker; and eGFR: estimated glomerular filtration rate.

| Variables                  | Univariate and multivariate logistic regression analysis of factors associated with Yang-deficiency among IgAN patients. |
|----------------------------|----------------------------------------------------------------------------------------------------------------------------------|
|                            | Variables | Univariate logistic regression | Multivariate logistic regression |
|                            |           | OR                        | 95% CI                    | P       | OR            | 95% CI                   | P       |
| Female (vs. male)          |           | 3.120                     | 2.060–4.725 | < 0.001 | 2.419         | 1.483–3.946 | < 0.001 |
| Age                       |           | 1.041                     | 1.018–1.064 | < 0.001 | 1.048         | 1.023–1.073 | < 0.001 |
| BMI                       |           | 0.991                     | 0.942–1.043 | 0.729   |               |              |        |
| MAP                       |           | 0.991                     | 0.976–1.006 | 0.257   |               |              |        |
| Total serum protein        |           | 0.977                     | 0.953–1.002 | 0.070   |               |              |        |
| ALB                       |           | 0.934                     | 0.899–0.970 | < 0.001 |               |              |        |
| Blood urea nitrogen        |           | 1.006                     | 0.938–1.078 | 0.877   |               |              |        |
| Serum creatinine           |           | 0.999                     | 0.995–1.003 | 0.533   |               |              |        |
| SUA                       |           | 0.998                     | 0.996–1.000 | 0.023   |               |              |        |
| Total cholesterol          |           | 1.080                     | 0.912–1.280 | 0.373   |               |              |        |
| Triglycerides              |           | 0.873                     | 0.734–1.037 | 0.123   |               |              |        |
| HDL-C                     |           | 2.091                     | 1.198–3.649 | 0.009   |               |              |        |
| LDL-C                     |           | 1.175                     | 0.933–1.479 | 0.170   |               |              |        |
| eGFR                      |           | 0.997                     | 0.991–1.004 | 0.418   |               |              |        |
| Urinary protein            |           | 1.070                     | 0.949–1.207 | 0.269   |               |              |        |
| Hb                        |           | 0.972                     | 0.962–0.983 | < 0.001 | 0.983         | 0.971–0.996 | 0.011   |
| URBC                      |           | 1.019                     | 1.007–1.030 | 0.001   |               |              |        |
| Immunosuppressant use      |           | 1.170                     | 0.782–1.751 | 0.445   |               |              |        |
| RASB use                  |           | 1.400                     | 0.712–2.751 | 0.329   |               |              |        |
| M1 (vs. M0)               |           | 0.765                     | 0.509–1.148 | 0.196   |               |              |        |
| E1 (vs. E0)               |           | 1.743                     | 1.072–2.835 | 0.025   |               |              |        |
| S1 (vs. S0)               |           | 1.130                     | 0.716–1.784 | 0.601   |               |              |        |
| T0                        |           | 1.000                     | Reference    | 0.851   |               |              |        |
| T1                        |           | 0.872                     | 0.543–1.400 | 0.571   |               |              |        |
| T2                        |           | 0.946                     | 0.555–1.611 | 0.837   |               |              |        |
| C1/C2 (vs. C0)            |           | 1.980                     | 1.281–3.061 | 0.002   | 1.845         | 1.154–2.949 | 0.010   |

BMI: body mass index; MAP: mean arterial pressure; ALB: albumin; SUA: serum uric acid; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; Hb: hemoglobin; URBC: urine red blood cell count; eGFR: estimated glomerular filtration rate; M: mesangial hypercellularity; E: endocapillary hypercellularity; S: segmental glomerulosclerosis or adhesion; T: tubular atrophy/interstitial fibrosis; C: cellular/fibrocellular crescents; and RASB: renin-angiotensin system blocker.
common complication in patients with middle and late stage of CKD, but is also evidence of a poor prognosis in patients with Yang-deficiency.

Anemia in TCM belongs to Blood-deficiency syndrome, Yin-deficiency syndrome, and so on. Yang-deficiency leads to insufficient gasification, which affects the movement of water valley essence in the spleen and stomach and then affects the process of blood production and transformation, resulting in Blood-deficiency. Qi is invisible; blood is the carrier of qi, and qi can be lost with the loss of blood, so blood deficiency can further aggravate qi deficiency. In TCM, Qi belongs to Yang; blood belongs to Yin. Yin and Yang are fundamental and can be transformed into each other, and Yin-deficiency can further lead to Yang-deficiency.

Exploring the correlation between pathological changes and TCM syndrome elements belongs to the microscopic syndrome differentiation. Because all pathological products are tangible, they are all positive, according to the theory of TCM. Thus, there is a theory of micro-syndrome differentiation without deficiency syndrome. Because of its attribute of growth, the formation of crescent can belong to Yang [31]. Previous studies have found that the deficiency syndrome of IgAN with crescent formation is mainly spleen–kidney Yang-deficiency syndrome [32]. We also found that cellular/fibrocellular crescents were positively correlated with Yang-deficiency in patients with IgAN, but the correlation between Yang-deficiency and crescent formation needs to be confirmed in a larger patient population.

In this study, eGFR and T lesions remained significant independent risk factors for a poor prognosis of IgAN in multivariate Cox regression analysis. However, MAP, M, E, and S lesions and the use of immunosuppressants were not statistically significantly associated in multivariate analysis. This was consistent with the results of multivariate Cox regression analysis of the full model, including race, of the International IgA Nephropathy Prediction Tool derivation cohort [5].

However, our results in terms of other indicators differed from those of this full model with race included. In this study, 24-hour urinary protein was an independent risk factor for poor prognosis in IgAN patients, while RASB and age were not statistically significant in multivariate Cox regression analysis. The quantity of urinary protein has been shown to be associated with poor prognosis in many studies [33–37]. The timing for renal biopsy in the patients included in this study ranged from 2013 to 2021, and the use rate of RASB inhibitors was 89.1%, which was significantly higher than that (32.4%) of patients included in the International IgA Nephropathy Prediction Tool derivation cohort, which had a median timing of renal biopsy of 2006. The 2012 KDIGO guidelines [38] recommend that patients with IgAN be routinely treated with RASB during or after biopsy. Due to the widespread use of RASB, its effect on prognosis is underestimated. Some previous studies had not found that RASB has an independent prognostic effect on IgAN [39, 40]. The effect of age on the prognosis of IgAN patients remains controversial [28, 33, 41, 42]. In this study, no effect of age on the prognosis of IgAN was found, which is related to the inclusion of age-related Yang-deficiency in the model.

This study had some limitations. First, this study was a single-center retrospective study, with an insufficient number of included patients. Second, the median follow-up period of 22 months was relatively short.

5. Conclusion

This study found that Yang-deficiency syndrome should be an independent risk factor for poor prognosis of IgAN. In turn, Yang-deficiency syndrome was related to sex, age, hemoglobin, and cellular/fibrocellular crescents. The combination of TCM syndrome elements and clinicopathological indexes may improve the clinical curative effect and delay the progress of IgAN to a certain extent.

Data Availability

The data presented in this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Authors’ Contributions

Jianghua Ke and Shuwei Duan contributed equally to this work.

Acknowledgments

The authors would like to thank all volunteers who participated in the study. This work was supported by the Science and Technology Project of Beijing, China (no. D181100000118002), the National Key Research and Development Program of China (no. 2019YFC1709903), and the National Natural Science Foundation of China (Project no. 32141005).

Supplementary Materials

Table S1. Baseline clinical and pathological characteristics of the 423 patients included and 155 patients followed <90 days. Table S2. Distribution of syndrome elements in the 423 patients included and 155 patients followed <90 days. Table S3. Distribution of CKD stages and 24 h urinary protein for patients at the time of renal biopsy with Yang-deficiency and non-Yang-deficiency. (Supplementary Materials)

References

[1] F. P. Schena and I. Nistor, “Epidemiology of IgA nephropathy: a global perspective,” Seminars in Nephrology, vol. 38, no. 5, pp. 435–442, 2018.
[2] K. N. Lai, S. C. Tang, F. P. Schena et al., “IgA nephropathy,” Nature Reviews Disease Primers, vol. 2, no. 1, Article ID 16001, 2016.
[3] A. McGrogan, C. F. M. Franssen, and C. S. de Vries, “The incidence of primary glomerulonephritis worldwide: a
systematic review of the literature,” *Nephrology Dialysis Transplantation*, vol. 26, no. 2, pp. 414–430, 2011.

[4] “KDIGO 2021 clinical practice guideline for the management of glomerular diseases,” *Kidney International*, vol. 100, 2021.

[5] S. J. Barbour, R. Coppo, H. Zhang et al., “Evaluating a new international risk-prediction tool in IgA nephropathy,” *JAMA Internal Medicine*, vol. 179, no. 7, pp. 942–952, 2019.

[6] J. Zhang, B. Huang, Z. Liu et al., “External validation of the international IgA nephropathy prediction tool,” *Clinical Journal of the American Society of Nephrology*, vol. 15, no. 8, pp. 1112–1120, 2020.

[7] Y. Zhang, L. Guo, Z. Wang et al., “External validation of international risk-prediction models of IgA nephropathy in an asian-caucasian cohort,” *Kidney International Reports*, vol. 5, no. 10, pp. 1753–1763, 2020.

[8] S. Li and J. P. Li, “Treatment effects of Chinese medicine (Yi-Qi-Qing-Jie herbal compound) combined with immunosuppression therapies in IgA nephropathy patients with high-risk of end-stage renal disease (TCM-WINE): study protocol for a randomized controlled trial,” *Trials*, vol. 21, no. 1, 2020.

[9] P. Li, Y. Z. Chen, H. L. Lin et al., “Abelmoschus manihot - a traditional Chinese medicine versus losartan potassium for treating IgA nephropathy: study protocol for a randomized controlled trial,” *Trials*, vol. 18, no. 1, p. 170, 2017.

[10] C. Xu, H. Xia, and Y. Y. Deng, “Effect of invigorating the spleen and kidney and dredging channels method combined with Prednisone in the treatment of progressive IgA nephropathy,” *China Medical Herald*, vol. 17, no. 18, pp. 87–90, 2020.

[11] W. F. Zhu, “Establishing a new system of syndrome differentiation with syndrome elements as the code,” *Journal of Traditional Chinese Medicine University of Hunan*, vol. 24, no. 6, pp. 38-39, 2004.

[12] Z. B. Zhang and Y. Y. Wang, “Research on TCM syndrome nomenclature and classification: review and hypothesis,” *Journal of Beijing University of Traditional Chinese Medicine*, vol. 26, 2003.

[13] Y. Y. Wang, Q. Q. Zhang, and Z. B. Zhang, “The induction of syndrome factor and affecting target,” *Journal of Shandong University of Traditional Chinese Medicine*, vol. 30, no. 1, pp. 6-7, 2006.

[14] Z. Zhijie, L. Shaoming, Z. Yueyang et al., “Traditional Chinese Medicine syndrome elements of male infertility revealed by latent tree model analysis,” *Journal of Traditional Chinese Medicine*, vol. 38, no. 6, pp. 926–935, 2018.

[15] J. Wei, R. Wu, and D. Zhao, “Analysis of TCM syndrome elements and relevant factors for senile diabetes,” *Journal of Traditional Chinese Medicine*, vol. 33, no. 4, pp. 473–478, 2013.

[16] S. Xia, J. Zhang, G. Du et al., “A microcosmic syndrome differentiation model for metabolic syndrome with multilabel learning,” *Evidence-based Complementary and Alternative Medicine*, vol. 2020, Article ID 9081641, 10 pages, 2020.

[17] L. Liu, Z. Yin, J. Ma, S. Duan, and X. Chen, “Potential association of body constitution with the prognosis of IgA nephropathy: a long-time follow-up of 203 cases in China,” *Evidence-based Complementary and Alternative Medicine*, vol. 2019, Article ID 6289478, 6 pages, 2019.

[18] X. M. Chen, Y. P. Chen, and P. Li, “A multi-center epidemiological survey on TCM syndrome in 1016 patients with IgA nephropathy and analysis of its relevant factors,” *Chinese Journal of Integrated Traditional and Western Medicine*, vol. 26, no. 3, pp. 197–201, 2006.

[19] J. Wang, P. Xie, J.-M. Huang et al., “The new Asian modified CKD-EPI equation leads to more accurate GFR estimation in Chinese patients with CKD,” *International Urology and Nephrology*, vol. 48, no. 12, pp. 2077–2081, 2016.

[20] H. Trimarchi, J. Barratt, D. C. Cattran et al., “Oxford classification of IgA nephropathy 2016: an update from the IgA nephropathy classification working group,” *Kidney International*, vol. 91, no. 5, pp. 1014–1021, 2017.

[21] G. Chen, P. Li, D. Zuo, and C. Xiangmei, “The relationship between syndrome differentiation of traditional Chinese medicine and the degree of pathological changes in IgA nephropathy patients,” *Chinese Journal of Information on Traditional Chinese Medicine*, vol. 11, no. 11, pp. 1020–1021, 2004.

[22] W. Liu, L. Shi, Q. Wan et al., “Decoction attenuates Podocyte cytoskeletal protein damage in IgA nephropathy rats by regulating AT1R/Nephrin/c-Abl pathway,” *Biomedicine & Pharmacotherapy*, vol. 142, 2021.

[23] Q. Q. Guo, P. J. Dai, H. R. Guo, X. L. Wang, and Y. X. He, “Progress in TCM diagnosis and treatment of chronic urinary tract infection in women with Yang-deficiency,” *Guangming Journal of Chinese Medicine*, vol. 34, no. 12, pp. 1805–1807, 2019.

[24] L. Z. Song, M. Y. Guo, J. Chen et al., “Analysis of TCM physique of normal people of different ages in Fuzhou area,” *Traditional Chinese Medicine Journal*, vol. 17, no. 3, pp. 44–47, 2018.

[25] Y. B. Zhu, Q. Wang, and S. L. Yao, “Study on the related influencing factors of yang-deficiency constitution in Chinese medicine,” *Journal of Traditional Chinese Medicine*, vol. 48, no. 12, 2007.

[26] D. Wen, Y. Tang, L. Tan et al., “Sex disparities in IgA nephropathy: a retrospective study in Chinese patients,” *International Urology and Nephrology*, vol. 53, no. 2, pp. 315–323, 2021.

[27] P. P. Huang, D. H. Shu, Z. Su, S. N. Luo, F. F. Xu, and F. Lin, “Association between lifestyle, gender and risk for developing end-stage renal failure in IgA nephropathy: a case-control study within 10 years,” *Renal Failure*, vol. 41, no. 1, pp. 914–920, 2019.

[28] Y. Liu, W. Wei, C. Yu et al., “Epidemiology and risk factors for progression in Chinese patients with IgA nephropathy,” *Medicina Clinica*, vol. 157, no. 6, pp. 267–273, 2021.

[29] Y. Tang, P. C. Shen, W. J. Zhang, and H. Li-qun Shuguang, “Correlatedness between Chinese medical syndromes and clinical prognosis of IgA nephropathy,” *Shanghai Journal of Traditional Chinese Medicine*, vol. 44, no. 5, pp. 27–30, 2010.

[30] C. H. Qu and D. C. Wang, “The relation between the level of hemoglobin and differentiation of TCM in chronic heart failure and clinical effect,” *Medical Journal of Chinese People’s Health*, vol. 20, no. 24, 2008.

[31] X. H. Chen, X. Y. Yu, and J. R. Mao, “Pathological changes and TCM microscopic syndrome differentiation of IgA nephropathy,” *Chinese Journal of Integrated Traditional and Western Nephrology*, vol. 15, no. 2, pp. 185–186, 2014.

[32] J. Chen, *The Study of Clinical Manifestation, Renal Pathology and TCM Syndrome of IgA Nephropathy with Partial*, China Academy of Chinese Medical Sciences, Beijing, China, 2016.

[33] Y. Hao, Y. Zhao, R. Huang, and P. Fu, “Analysis of the relationship between Oxford classification, IgM deposition and multiple indexes and the adverseprognosis of patients with primary IgA nephropathy and related risk factors,” *Experimental and Therapeutic Medicine*, vol. 17, no. 2, pp. 1234–1239, 2019.
[34] R. Mohd, N. E. M. Kazmin, R. A. Cader et al., "Long term outcome of immunoglobulin A (IgA) nephropathy: a single center experience," *PLoS One*, vol. 16, 2021.

[35] W. Le, S. Liang, Y. Hu et al., "Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population," *Nephrology Dialysis Transplantation*, vol. 27, no. 4, pp. 1479–1485, 2012.

[36] H. N. Reich, S. Troyanov, J. W. Scholey, and D. C. Cattran, "Remission of proteinuria improves prognosis in IgA nephropathy," *Journal of the American Society of Nephrology*, vol. 18, no. 12, pp. 3177–3183, 2007.

[37] F. Berthoux, H. Mohey, B. Laurent, C. Mariat, A. Afiani, and L. Thibaudin, "Predicting the risk for dialysis or death in IgA nephropathy," *Journal of the American Society of Nephrology*, vol. 22, no. 4, pp. 752–761, 2011.

[38] KDIGO, "KDIGO clinical practice guideline for glomerulonephritis," *Kidney International*, vol. 2, pp. 139–274, 2012.

[39] X. Zhu, H. Li, Y. Liu et al., "Tubular atrophy/interstitial fibrosis scores of Oxford classification combined with proteinuria level at biopsy provides earlier risk prediction in IgA nephropathy," *Scientific Reports*, vol. 7, no. 1, p. 1100, 2017.

[40] Y. Miyabe, K. Karasawa, K. Akiyama et al., "Grading system utilising the total score of Oxford classification for predicting renal prognosis in IgA nephropathy," *Scientific Reports*, vol. 11, no. 1, p. 3584, 2021.

[41] F. Ma, L. Liu, R. Dong et al., "Renal survival and risk factors in IgA nephropathy with crescents," *International Urology and Nephrology*, vol. 52, no. 8, pp. 1507–1516, 2020.

[42] D. Chen, J. Liu, S. Duan et al., "Clinicopathological features to predict progression of IgA nephropathy with mild proteinuria," *Kidney & Blood Pressure Research*, vol. 43, no. 2, pp. 318–328, 2018.